---
document_datetime: 2023-09-21 17:46:45
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/olanzapine-teva-epar-procedural-steps-taken-authorisation_en.pdf
document_name: olanzapine-teva-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5574775
conversion_datetime: 2025-12-28 00:33:44.106749
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Teva  Pharma  B.V  submitted  on  04  December  2006  an  application  for  Marketing Authorisation to the European Medicines Agency (EMEA) for Olanzapine Teva, in accordance with the centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 3 (3) - 'Generic of a Centrally authorised product'.

The application legal basis refers to Article 10(1).

## The chosen reference product is:

- ■ Reference medicinal product which is or has been authorised for not less than 6/10 years in the EEA:
-  Product name, strength, pharmaceutical form:
- Zyprexa 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg coated tablets
-  Marketing authorisation holder: Eli Lilly Nederland B.V.
-  First authorisation:  Date (yyyy-mm-dd) 1996-09-27 Member State (EEA)/Community:  Community
- ■ Reference medicinal product authorised in the Community/Member State where the application is made:

## Film-coated tablets :

-  Product name, strength, pharmaceutical form:

Zyprexa 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg coated tablets

-  Marketing authorisation holder: Eli Lilly Nederland B.V.
-  Marketing authorisation number(s):EU/1/96/022

## Orodispersible tablets :

-  Product name, strength, pharmaceutical form:

Zyprexa Velotab  5, 10, 15, 20 mg orodispersible tablet

-  Marketing authorisation holder: Eli Lilly Nederland B.V.
-  Marketing authorisation number(s): EU/1/99/125

## ■ Medicinal Product used for bioequivalence study

-  Product name, strength, pharmaceutical form:  Zyprexa 10 mg coated tablet
-  Marketing authorisation holder: Eli Lilly Nederland B.V.
-  Member State of source: United Kingdom
-  Product name, strength, pharmaceutical form:  Zyprexa 20 mg coated tablet
-  Marketing authorisation holder: Eli Lilly Nederland B.V.
-  Member State of source: Germany
-  Product name, strength, pharmaceutical form: Zyprexa Velotab 10 mg orodispersible tablet
-  Marketing authorisation holder: Eli Lilly Nederland B.V.
-  Member State of source: United Kingdom
-  Product name, strength, pharmaceutical form: Zyprexa Velotab 20 mg orodispersible tablet
-  Marketing authorisation holder: Eli Lilly Nederland B.V.
-  Member State of source: Germany

The Rapporteur appointed by the CHMP was:

Rapporteur Dr. B. van Zwieten - Boot

<div style=\"page-break-after: always\"></div>

## Scientific Advice:

The applicant did not seek scientific advice at the CHMP.

## Licensing status:

Olanzapine Teva was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 04 December 2006.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 20 March 2007 .
- The procedure started on 27 December 2006.
- During  the  meeting  on  23-26  April  2007,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  26 April 2007.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 25 July 2007.
- The Rapporteur circulated  the  Assessment  Report  on  the  applicant's  responses  to  the  List  of Questions to all CHMP members on  21 September 2007 .
- During  the  meeting  on  15  -  18  October  2007,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting  a  Marketing  Authorisation  to  Olanzapine  Teva  on  18  October  2007.  The  applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 9 October 2007.